Therma Bright Inc. announced that it will test the SARS-CoV-2 (COVID-19) Delta variant, first detected in India, with its AcuVidTM antigen saliva test. Governments and global health experts have expressed deep concerns that the highly contagious, fast spreading Delta variant will add to a new wave of COVID-19 viral infections globally later this summer and fall. The Delta variant has already become the dominant version of the SARS-CoV-2 (COVID-19) virus in the United Kingdom and has been detected in at least 74 other countries worldwide, In addition, the Company has received the final 7 outstanding RT-PCR test results from the Brazilian study to match against its AcuVidTM saliva test, exceeding the minimum requirements of 30 positive/30 negative results for its FDA Emergency Use Authorization (EUA) submission. The study results will also be used for ANVISA (Brazil) and INVIMA (Colombia) submissions, as well as to further support the CE approval received in April 2021. Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.